Additional payments for achievement of specific development and regulatory approval events.

No definition available.

Name:	idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Aggregate potential milestone payments.

+ References

No definition available.

+ Details

Name:	idya_AggregatePotentialMilestonePayments
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Certain commercial sales milestones payment to be paid.

+ References

No definition available.

+ Details

Name:	idya_CertainCommercialSalesMilestonesPaymentToBePaid
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commercial milestone payments.

+ References

No definition available.

+ Details

Name:	idya_CommercialMilestonePayments
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Development and regulatory milestone payment to be paid.

+ References

No definition available.

+ Details

Name:	idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development and regulatory milestone payment to be received.

+ References

No definition available.

+ Details

Name:	idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Development milestone payments of phase three relating to first and second tumor histologies.

+ References

No definition available.

+ Details

Name:	idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development milestone payments of phase two relating to first and second tumor histologies.

+ References

No definition available.

+ Details

Name:	idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone payment.

+ References

No definition available.

+ Details

Name:	idya_MilestonePayment
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payment paid.

+ References

No definition available.

+ Details

Name:	idya_MilestonePaymentPaid
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payments relating to first and second tumor histologies.

+ References

No definition available.

+ Details

Name:	idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment of one-time option exercise fee.

+ References

No definition available.

+ Details

Name:	idya_PaymentOfOneTimeOptionExerciseFee
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment of option exercise fee.

+ References

No definition available.

+ Details

Name:	idya_PaymentOfOptionExerciseFee
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Total milestone payment to be received.

+ References

No definition available.

+ Details

Name:	idya_TotalMilestonePaymentToBeReceived
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	idya_UpfrontPayment
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

+ Details

Name:	us-gaap_PreferredStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=idya_NovartisInternationalPharmaceuticalsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=idya_SeriesBRedeemableConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=idya_BiocytogenPharmaceuticalsBeijingCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=idya_JiangsuHengruiPharmaceuticalsCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=idya_ServierLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Agreements - Additional Information (Details) $ in Millions		1 Months Ended
	Jul. 31, 2024 USD ($)	Oct. 31, 2025 USD ($)	Aug. 31, 2025 USD ($)	Apr. 30, 2025 USD ($)	Apr. 30, 2023 GBP (£)	Jan. 31, 2022 GBP (£)	Sep. 30, 2018 USD ($) shares	Jun. 30, 2026 GBP (£) shares	Dec. 31, 2025 shares	Dec. 31, 2024 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Preferred stock, shares issued \| shares								0	0
License Agreement \| Novartis International Pharmaceuticals Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment							$ 2.5
Milestone payment paid				$ 1.0
License Agreement \| Novartis International Pharmaceuticals Limited \| Series B Redeemable Convertible Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Preferred stock, shares issued \| shares							263,615
License Agreement \| Cancer Research Technology and the University of Manchester
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of one-time option exercise fee \| £						£ 250,000
Milestone payments relating to first and second tumor histologies \| £					£ 750,000
Maximum \| License Agreement \| Novartis International Pharmaceuticals Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Certain clinical and regulatory development milestones, agreed to make a payment							$ 8.0
Certain commercial sales milestones, agreed to make a payment							$ 20.0
Maximum \| License Agreement \| Cancer Research Technology and the University of Manchester
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional payments for achievement of specific development and regulatory approval events \| £								£ 18,750,000
Milestone payments of phase two relating to first and second tumor histologies \| £								1,500,000
Milestone payments of phase three relating to first and second tumor histologies \| £								£ 2,250,000
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of option exercise fee	$ 6.5
Milestone payment	5.0
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive development and regulatory milestone payments	95.0
Total potential milestone payments	$ 395.0
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total milestone payments										$ 1,045.0
Milestone payment		$ 2.0
Jiangsu Hengrui Pharmaceuticals Co., Ltd \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive development and regulatory milestone payments										$ 198.0
Servier License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment			$ 210.0
Servier License Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive development and regulatory milestone payments			100.0
Commercial milestone payments			$ 220.0